Trial Outcomes & Findings for Comparison of Steroid Dosages on the Efficacy of Trochanteric Bursa Injection (NCT NCT02126878)
NCT ID: NCT02126878
Last Updated: 2021-10-19
Results Overview
COMPLETED
NA
120 participants
3 month
2021-10-19
Participant Flow
The study was ended and the PI has left the institution. The numbers presented are what was initially entered by the research team. From data available, 120 participants were enrolled on the study; no information about those participants could be located. No other data could be located and it cannot be determined which arm the120 participants were enrolled in or if they completed the study.
Participant milestones
| Measure |
Kenaglog 20mg
20mg/ 2ml and local anesthetic
Kenalog
|
Kenalog 40mg
40mg/ 2ml with local anesthetic
Kenalog
|
Kenalog 80mg
80mg/ 2ml and local anesthetic
Kenalog
|
|---|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Comparison of Steroid Dosages on the Efficacy of Trochanteric Bursa Injection
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 3 monthPopulation: The study was ended and the PI has left the institution. No results information is available, all efforts were to made to retrieve results information, but were unsuccessful. No study data is available.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline, 1 month, 3 monthPopulation: The study was ended and the PI has left the institution. No results information is available, all efforts were to made to retrieve results information, but were unsuccessful. No study data is available.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 1 month,3 monthsPopulation: The study was ended and the PI has left the institution. No results information is available, all efforts were to made to retrieve results information, but were unsuccessful. No study data is available.
Outcome measures
Outcome data not reported
Adverse Events
Kenaglog 20mg
Kenalog 40mg
Kenalog 80mg
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Clinical Trials Compliance Coordinator
West Virginia Universtiy, WVCTSI
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place